Drawing for DUOJENTA

USPTO serial 85377431

DUOJENTA

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
BUCHANAN WILL, NORA
Law office
OFFICE OF TRADEMARK PROGRAM CONTROL

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DUOJENTA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Martin J. Bertan

MARTIN J. BERTAN OSTROLENK FABER LLP1180 AVENUE OF THE AMERICAS FL 7NEW YORK, NY 10036-8443UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 19, 2011MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Oct 19, 2011ABN5ABANDONMENT - AFTER PUBLICATION—
Oct 18, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 5, 2011MAILPAPER RECEIVED—
Sep 28, 2011NPUBNOTICE OF PUBLICATION—
Sep 12, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 12, 2011DOCKASSIGNED TO EXAMINER—
Jul 26, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 25, 2011NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance